UK and US Stem Cell Banks team up to share expertise
Plan to drive forward stem cell research
The UK and UMASS Stem Cell Banks have signed a Memorandum of Understanding (MOU) that will outline plans for cooperation in a variety of stem cell areas including the delivery of stem cell lines for clinical use.
The agreement outlines plans for the two stem cell banks to work together to ensure that best practice and high standards in stem cell banking are employed at both sites. They will also develop international training events for scientists involved in stem cell research.
Stem cells are the body's 'master cells', with the potential to become many different types of tissue. It is hoped that stem cell treatments may be used in future to help people with Parkinson's disease, diabetes or multiple sclerosis by repairing and replacing diseased and damaged body tissue.
The UK Stem Cell Bank, funded by the Medical Research Council and the Biotechnology and Biological Sciences Research Council, is a repository for human cell lines, derived from stem cells. It also holds new and existing adult, foetal and embryonic stem cell lines. Stem cell lines are provided only to accredited researchers to ensure the safe and ethical development of any potential stem cell therapy.
Dr Stephen Inglis, director of HPA's NIBSC said: ‘International co-operation is vital in this fast moving field and we expect that the partnership will accelerate the development of important new therapies, as well as keeping the UK at the forefront of stem cell research.’
Joseph Laning, senior director of the Human Stem Cell Bank and Registry at UMASS Medical School, added: ‘Both banks share common goals and needs. Working in concert allows us to develop strategies that will shape stem cell production, characterisation, banking and distribution in a dynamic field. Each bank brings its own unique attributes to bear in a way that will enhance our influence in the field.’
You may also like
Trending Articles
You may also like
Drug Delivery
Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody
The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development
FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design
The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline
Research & Development
Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive
Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
Research & Development
Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic
Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
Research & Development
Early stage clinical trials highlight the convergence of novel therapeutics and enabling technologies
Early stage clinical development is increasingly being shaped by advances in drug discovery and the technologies and manufacturing strategies that enable the safe, precise and scalable delivery of new therapies